These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32742988)

  • 1. Adjuvant nab-paclitaxel plus gemcitabine
    Yin ZZ; Zhao ZM; Tang WB; Jiang N; Zhang KD; Song YY; Wang Y; Li CG; Gao YX; Liu R
    World J Clin Cases; 2020 Jul; 8(13):2778-2786. PubMed ID: 32742988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study.
    Li H; Guo Y; Sun X; Lu Y; Chang S; Wang X; Gao S; Gao C; Zhao T
    Front Oncol; 2023; 13():1276037. PubMed ID: 37909023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.
    Scheithauer W; Ramanathan RK; Moore M; Macarulla T; Goldstein D; Hammel P; Kunzmann V; Liu H; McGovern D; Romano A; Von Hoff DD
    J Gastrointest Oncol; 2016 Jun; 7(3):469-78. PubMed ID: 27284481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis.
    Chae H; Jeong H; Cheon J; Chon HJ; Ryu H; Kim IH; Kang MJ; Jeong JH; Ryoo BY; Kim KP; Yoo C
    Ther Adv Med Oncol; 2020; 12():1758835920923424. PubMed ID: 32523632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. French multi-institutional cost-effectiveness analysis of gemcitabine plus nab-paclitaxel
    Demaziere A; Mourgues C; Lambert C; Trevis S; Bertucat H; Grange I; Pezet D; Sautou V; Jary M; Gagnière J
    Ther Adv Med Oncol; 2024; 16():17588359241259635. PubMed ID: 38882442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial.
    Postlewait LM; Ethun CG; Kooby DA; Sarmiento JM; Chen Z; Staley CA; Brutcher E; Adsay V; El-Rayes B; Maithel SK
    J Surg Oncol; 2016 Sep; 114(3):336-41. PubMed ID: 27501338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia.
    Rogers JE; Mizrahi JD; Shroff RT; Nelson DA; Tu J; Javle MM; Wolff RA; Pant S
    J Gastrointest Oncol; 2020 Feb; 11(1):55-60. PubMed ID: 32175105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data.
    Giovinazzo F; Soggiu F; Jang JY; Versteijne E; van Tienhoven G; van Eijck CH; Han Y; Choi SH; Kang CM; Zalupski M; Ahmad H; Yentz S; Helton S; Rose JB; Takishita C; Nagakawa Y; Abu Hilal M
    Front Oncol; 2020; 10():1112. PubMed ID: 32850319
    [No Abstract]   [Full Text] [Related]  

  • 9. Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort.
    Wu H; Huang N; Zhao C; Hu X; Da L; Huang W; Shen Y; Xiong F; Zhang C
    Ann Transl Med; 2022 Mar; 10(6):294. PubMed ID: 35433955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world outcomes of adjuvant gemcitabine
    Kang S; Yoo C; Lee SH; Oh D; Song TJ; Lee SS; Jeong JH; Park DH; Seo DW; Park JH; Hwang DW; Song KB; Lee JH; Lee W; Kwak BJ; Hong S; Chang HM; Ryoo BY; Kim KP; Kim SC
    Ther Adv Med Oncol; 2022; 14():17588359221097190. PubMed ID: 35571606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma.
    Zong Y; Peng Z; Wang X; Lu M; Shen L; Zhou J
    Cancer Manag Res; 2020; 12():12657-12666. PubMed ID: 33328763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayesian network meta-analysis.
    de Jesus VHF; Riechelmann RP
    Ecancermedicalscience; 2021; 15():1276. PubMed ID: 34567261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma.
    de Jong EJM; Janssen QP; Simons TFA; Besselink MG; Bonsing BA; Bouwense SAW; Geurts SME; Homs MYV; de Meijer VE; Tjan-Heijnen VCG; van Laarhoven HWM; Valkenburg-van Iersel LBJ; Wilmink JW; van der Geest LG; Koerkamp BG; de Vos-Geelen J;
    Int J Cancer; 2022 May; 150(10):1654-1663. PubMed ID: 34935139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.
    Javed MA; Beyer G; Le N; Vinci A; Wong H; Palmer D; Morgan RD; Lamarca A; Hubner RA; Valle JW; Alam S; Chowdhury S; Ma YT; Archibugi L; Capurso G; Maisonneuve P; Neesse A; Sund M; Schober M; Krug S
    Pancreatology; 2019 Jan; 19(1):97-104. PubMed ID: 30529068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment.
    Bianconi D; Herac M; Spies D; Kieler M; Brettner R; Unseld M; Fürnkranz K; Famler B; Schmeidl M; Minichsdorfer C; Zielinski C; Heller G; Prager GW
    Transl Oncol; 2019 Jan; 12(1):15-23. PubMed ID: 30245304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study.
    Zhang F; Wang Y; Yang F; Zhang Y; Jiang M; Zhang X
    Cancer Manag Res; 2022; 14():535-546. PubMed ID: 35173487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOLFIRINOX
    Cho IR; Kang H; Jo JH; Lee HS; Chung MJ; Park JY; Park SW; Song SY; An C; Park MS; Bang S
    World J Gastrointest Oncol; 2020 Feb; 12(2):182-194. PubMed ID: 32104549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy.
    Mortier V; Wei F; Pellat A; Marchese U; Dohan A; Brezault C; Barat M; Fuks D; Soyer P; Coriat R
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus
    Tajima H; Makino I; Gabata R; Okazaki M; Ohbatake Y; Shimbashi H; Nakanuma S; Saitoh H; Shimada M; Yamaguchi T; Okamoto K; Moriyama H; Kinoshita J; Nakamura K; Miyashita T; Ninomiya I; Fushida S; Ikeda H; Ohta T
    Mol Clin Oncol; 2021 Feb; 14(2):26. PubMed ID: 33414907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis.
    Cheon J; Lee CK; Sang YB; Choi HJ; Kim MH; Ji JH; Ko KH; Kwon CI; Kim DJ; Choi SH; Kim C; Kang B; Chon HJ
    Ther Adv Med Oncol; 2021; 13():17588359211035983. PubMed ID: 34394748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.